Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.
We noticed you have an ad blocker enabled. Please whitelist us so we can continue to provide free content.